Published in Atherosclerosis on December 01, 1994
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2001) 3.60
Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia (2011) 1.85
Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res (2000) 1.78
Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet (1998) 1.63
Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol (2000) 1.53
Obesity, haemostasis and the fibrinolytic system. Obes Rev (2002) 1.40
Familial adenomatous polyposis coli in South Africa--molecular basis and diagnosis. S Afr Med J (2000) 1.39
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) (2006) 1.22
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab (2012) 1.19
A RFLP associated with the low-density lipoprotein receptor gene (LDLR). Nucleic Acids Res (1987) 1.17
Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res (2003) 1.06
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab (2003) 1.04
Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord (2001) 1.00
High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab (1999) 0.98
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]. Rev Med Liege (2010) 0.95
Haplotype associations of three DNA polymorphisms at the human low density lipoprotein receptor gene locus in familial hypercholesterolaemia. J Med Genet (1987) 0.93
Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb (1993) 0.92
Haplotypes identified by 10 DNA restriction fragment length polymorphisms at the human low density lipoprotein receptor gene locus. J Med Genet (1989) 0.92
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab (2004) 0.92
The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners. Ann Hum Genet (1991) 0.90
Diabetic ketoacidosis-induced hyperkalemia. Prevalence and possible origin. Intensive Care Med (1986) 0.90
Hemoperfusion-hemodialysis ineffective for paraquat removal in life-threatening poisoning? J Toxicol Clin Toxicol (1985) 0.89
The identification of two low-density lipoprotein receptor gene mutations in South African familial hypercholesterolaemia. S Afr Med J (1989) 0.89
Helicobacter pylori, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus. Aliment Pharmacol Ther (2002) 0.87
Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutations. PCR Methods Appl (1995) 0.86
Molecular characterisation of a low-frequency mutation in exon 8 of the human low-density lipoprotein receptor gene. S Afr Med J (1989) 0.84
Anthropometric and calorimetric evidence for the protein sparing effects of a new protein supplemented low calorie preparation. Am J Clin Nutr (1985) 0.84
CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet (1997) 0.84
Gastric parietal cell antibodies are associated with glutamic acid decarboxylase-65 antibodies and the HLA DQA1*0501-DQB1*0301 haplotype in Type 1 diabetes mellitus. Belgian Diabetes Registry. Diabet Med (2000) 0.83
Genetic association between WNT10B polymorphisms and obesity in a Belgian case-control population is restricted to males. Mol Genet Metab (2011) 0.83
Intrafamilial variability in the clinical expression of familial hypercholesterolemia: importance of risk factor determination for genetic counselling. Clin Genet (1993) 0.83
Detection of a frequent polymorphism in exon 10 of the low-density lipoprotein receptor gene. Hum Genet (1992) 0.82
Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics. Hum Genet (1997) 0.82
Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet (1998) 0.81
Familial defective apolipoprotein-B is rare in hypercholesterolaemic South African Afrikaners, coloureds and Indians. S Afr Med J (1995) 0.81
Mutation -59c-->t in repeat 2 of the LDL receptor promoter: reduction in transcriptional activity and possible allelic interaction in a South African family with familial hypercholesterolaemia. Hum Mol Genet (1999) 0.81
Mutation analysis reveals an insertional hotspot in exon 4 of the LDL receptor gene. Hum Genet (1996) 0.80
Improved visualization of the Bst EII RFLP of the human LDL receptor gene by co-digestion. Nucleic Acids Res (1987) 0.79
Serum and erythrocyte magnesium levels in type I and type II diabetics. Acta Diabetol Lat (1986) 0.79
Screening for mutations in exon 4 of the LDL receptor gene: identification of a new deletion mutation. J Med Genet (1995) 0.79
Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol (1994) 0.78
Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners. Genet Couns (1994) 0.78
Detection of two point mutations causing familial defective apolipoprotein B-100 by heteroduplex analysis. Mol Cell Probes (1994) 0.78
An exon 4 mutation identified in the majority of South African familial hypercholesterolaemics. J Med Genet (1990) 0.78
High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary haemochromatosis in South Africa. S Afr Med J (1999) 0.78
FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (1995) 0.78
Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. Diabetes Care (2000) 0.78
[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]. Rev Med Liege (2008) 0.78
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. Rev Med Liege (2012) 0.77
In vitro expression of alpha-L-fucosidase activity polymorphism observed in plasma. Hum Genet (1983) 0.77
Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant (1996) 0.77
New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost (2006) 0.77
A de novo duplication in the low density lipoprotein receptor gene. Hum Mutat (1995) 0.76
Two novel frameshift mutations in the low density lipoprotein receptor gene generated by endogenous sequence-directed mechanisms. Hum Genet (1995) 0.76
Recurrent LDL-receptor mutation causes familial hypercholesterolaemia in South African coloureds and Afrikaners. S Afr Med J (1995) 0.76
Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clin Genet (1998) 0.76
Screening for genetic variants in BDNF that contribute to childhood obesity. Pediatr Obes (2013) 0.76
18q-syndrome with coeliac disease. Eur J Pediatr (1999) 0.76
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev Med Liege (2007) 0.76
Metabolic disregulation in obese adolescents with sleep-disordered breathing before and after weight loss. Obesity (Silver Spring) (2013) 0.76
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. Rev Med Liege (2010) 0.76
Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report. J Diabetes Complications (2000) 0.75
Body fat, body fat distribution and the respiratory system: a "fat neck" syndrome? Eur Respir J (1992) 0.75
[Endocannabinoid system in the brain...and elsewhere]. Rev Med Liege (2008) 0.75
Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics. Mol Cell Probes (2001) 0.75
Subregional mapping of the human lymphocyte prolyl oligopeptidase gene (PREP) to human chromosome 6q22. Cytogenet Cell Genet (1996) 0.75
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. Rev Med Liege (2008) 0.75
No conclusive evidence for association of polymorphisms in the adiponectin receptor 1 gene, AdipoR1, with common obesity. Endocrine (2012) 0.75
Insulinotropic effect of different formula of very low calorie protein supplemented diets in obesity. Acta Clin Belg (1987) 0.75
A rare silent G to T mutation in exon 4 of the human low density lipoprotein receptor gene. Clin Genet (1995) 0.75
Perioperative parenteral nutrition in the stressed diabetic patient. World J Surg (1986) 0.75
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]. Rev Med Liege (2011) 0.75
[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. Rev Med Liege (2009) 0.75
Effects of smoking on lipid parameters during therapeutic weight loss. Atherosclerosis (1986) 0.75
Influence of mebendazole administration on metabolic control in type 1 (insulin-dependent) diabetic patients. Diabetologia (1985) 0.75
[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]. Rev Med Liege (2005) 0.75
Decreased diet-induced thermogenesis in gluteal-femoral obesity. J Am Coll Nutr (1989) 0.75
The "endocrine" dysmetabolism of visceral obesity. Lessons from exercise research. Eur J Med (1993) 0.75
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. Rev Med Liege (2008) 0.75
A case of malnutrition after biliopancreatic diversion for morbid obesity. Int J Obes Relat Metab Disord (1993) 0.75
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]. Rev Med Liege (2010) 0.75
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]. Rev Med Liege (2013) 0.75
Incidence of low-fluorescence alpha satellite region on chromosome 21 escaping detection of aneuploidy at interphase by FISH. Cytogenet Cell Genet (1995) 0.75
Promising new approaches to the management of obesity. Drugs (2000) 0.75
Assignment of the mouse Extl1 gene to the distal part of chromosome 4 by in situ hybridization and radiation hybrid mapping. Cytogenet Cell Genet (2001) 0.75
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]. Rev Med Liege (2005) 0.75
Intronic mutations at splice junctions in the low-density lipoprotein receptor gene. Mol Cell Probes (1999) 0.75